By: Benzinga
UPDATE: Goldman Sachs Upgrades Vertex Pharmaceuticals to Neutral on '661/Kalydeco Data
In a report published Friday, Goldman Sachs analyst Terence Flynn upgraded the rating on Vertex Pharmaceuticals (NASDAQ: VRTX ) from Sell to Neutral, and raised the price target from $38.00 to $86.00. In the report, Flynn noted, “We are upgrading VRTX to Neutral from Sell. Since being added to the
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here